Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DPA-714 PET for Neuroinflammation in Breast Cancer
NCT04364672Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2025
- Primary completion
- Jul 2026
01
Overview
Phase 1, open-label, single-arm trial of DPA-714 in breast cancer, sponsored by University of Alabama at Birmingham. Primary endpoint: Regional brain TSPO levels using [F-18]DPA-714-PET at 12 weeks. Planned start Jun 2025; status: withdrawn.
02
Drugs
DPA-714
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04364672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364672.